Comparison of Effects of EBV-DNA on IMRT and DW-MRI Guided SIB-IMRT in Locally Advanced Nasopharyngeal Carcinoma: a Phase II Randomised Controlled Trial

INTERVENTION: group B (DW‐MRI guided SIB‐IMRT group):diffusion weighted magnetic Resonance Imaging (DW‐MRT) guided simultaneous integrated boost intensity‐modulated radiation therapy (SIB‐IMRT);group A (control group):anatomical image‐based intensity‐modulated radiation therapy (IMRT); CONDITION: nasopharyngeal carcinoma PRIMARY OUTCOME: overall survival (OS); SECONDARY OUTCOME: disease‐free survival (DFS);distant metastasis‐free survival (DMFS);local recurrence‐free survival (LRFS);regional recurrence‐free survival;loco‐regional recurrence‐free survival (LRRFS);response rates;toxic effects; INCLUSION CRITERIA: Eligible patients will be 18 to 70 years ages with non‐distant metastatic, histologically proven WHO types II‐III, stage T3‐4N0‐3M0 nasopharyngeal carcinoma (8th Union for International Cancer Control, UICC). All participants have Karnofsky scores of at least 70, and adequate bone marrow (leukocyte count =4.0×109/L, absolute neutrophil count =1.5×10^9/L, platelets =100×10^9/L), liver, and renal functions. Patients are required to provide written informed consent before undergoing chemoradiotherapy.